Hims & Hers Health Inc. (HIMS) saw its stock soar 5.22% in intraday trading on Thursday, outperforming the broader market. This surge was fueled by attention and buzz surrounding the telehealth company's provocative Super Bowl commercial criticizing weight-loss drug makers and the U.S. healthcare system.
While the controversial ad has prompted backlash from Senators Richard Durbin and Roger Marshall, who have requested an FDA investigation into potential misleading claims, it has also generated significant publicity for the company. Investors appear to be anticipating positive news from Hims & Hers' upcoming earnings report scheduled for February 24th, which could provide further insight into its performance and outlook.
Despite the controversy, Hims & Hers remains a highly rated stock in its industry group, with strong rankings for its Composite Rating, EPS Rating, and Relative Strength Rating. The stock's rally highlights the market's interest in the company and its ability to capitalize on the attention generated by its bold marketing strategy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.